HERTZLIYA, Israel, April 4, 2012 /PRNewswire/ --
Rainbow Medical, a leader in Medical Device innovation, is pleased to announce the promotion of Mr. Ron A. Tavlin to the post of Executive Vice President. Ron joined Rainbow Medical in 2010 as Vice President of Strategy and Business Development and has been instrumental in developing and leading our strategic focus and building our global strategic alliances and partnerships. Rainbow Medical CEO Mr. Efi Cohen Arazi made the announcement.
Commenting on the announcement, Mr. Cohen Arazi said; “Ron has forged a global network of strategic opportunities for Rainbow Medical and has shown great leadership and understanding in positioning the company for future strategic growth”. “We congratulate him on this promotion and are delighted to have Ron be an integral part of the executive team” added Cohen Arazi.
Ron joined Rainbow Medical with more than 25 years of private equity, venture capital and operational experience. Prior to joining Rainbow Medical, Ron founded and worked for 18 years as Managing Director of Omega Capital and Asset Management, a firm dedicated to early stage funding, investment banking, M&A and operational advisory services. Before founding Omega Capital, Ron was Senior Vice President of Corporate Development and Strategy at Litton Industries with global M&A and business development responsibility. Ron held senior operational roles as general manager of numerous global business units. Ron holds a BSEE in Electrical Engineering from City College of New York and an MBA from the Stern School of Management at New York University.
About Rainbow Medical
Rainbow Medical Ltd. is a privately owned Israeli company with the aim of seeding and accelerating medical device companies that develop breakthrough technologies in a diverse range of therapeutic areas.
RMD’s current portfolio consists of 11 operational subsidiary companies and more than 30 medical technology, or med-tech, patent applications, which comprise its pipeline portfolio. Utilizing the intellectual property (“IP”) contained in its pipeline portfolio, the Company intends to incorporate future subsidiary companies based on market and scientific analysis of its patent applications in order to grow and further develop its portfolio.
RMD’s patent portfolio is based on the inventions and developments of its co-founder and chief technology officer, Yossi Gross. To date, Yossi Gross has filed over 600 patents and is highly respected among leading U.S. and Israeli corporations and venture investors. Additionally Yossi Gross has founded over 27 companies in a wide range of advanced medical technologies and significant strategic relationships with multinational corporations.
For more information visit: http://www.rainbowmd.com
Contact:
Etti Lavian
Rainbow Medical Ltd.
Phone: +972-9-9531120
etti@rainbowmd.com
SOURCE Rainbow Medical Ltd
